- Home
- ABBV
ABBV
AbbVie Inc.
as 03-28-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 370.7B | IPO Year: | N/A |
| Target Price: | $212.70 | AVG Volume (30 days): | 6.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.39 | EPS Growth: | -12.13 |
| 52 Week Low/High: | $153.58 - $218.66 | Next Earning Date: | 04-25-2025 |
| Revenue: | $56,334,000,000 | Revenue Growth: | 3.71% |
| Revenue Growth (this year): | 7.74% | Revenue Growth (next year): | 8.02% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '25 | Sell | $207.30 | 27,900 | $5,822,401.63 | 11,793 | |
| GONZALEZ RICHARD A | ABBV | Director | Feb 28 '25 | Sell | $207.82 | 98,628 | $20,263,019.64 | 388,929 | |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Feb 28 '25 | Sell | $210.59 | 21,250 | $4,472,038.78 | 6,130 | |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Feb 26 '25 | Sell | $202.86 | 29,917 | $6,070,036.16 | 6,130 | |
| Buckbee Kevin K | ABBV | SVP, CONTROLLER | Feb 26 '25 | Sell | $203.41 | 18,944 | $3,853,372.20 | 11,496 | |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 20 '25 | Sell | $197.76 | 5,778 | $1,143,452.88 | 11,793 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
3 Relatively Safe Stocks to Buy Right Now
Zacks
4 days ago
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks
4 days ago
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
GuruFocus.com
4 days ago
CollPlant Biotechnologies Ltd (CLGN) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Simply Wall St.
4 days ago
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip
PR Newswire
5 days ago
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
Barrons.com
5 days ago
These Dividend Stocks Can Protect You From the Next Market Drop
Motley Fool
5 days ago
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.